Vol.54 No.6 November 2006
A multicenter study of 7-day cefcapene pivoxil treatment for group A streptococcal infection
Department of Pediatrics, Asahikawa Kosei Hospital, 1-24, Asahikawa, Hokkaido, Japan
Abstract
Between July 2005 and September 2005, we enrolled 129 children with group A streptococcal infection in a prospective multicenter study. Children aged from 6 months to 15 years (5.2±2.4 years) treated with cefcapene pivoxil 9 mg/kg/day tid for 7 days were evaluated for clinical efficacy and bacterial effect at the end of therapy and were observed for the occurrence of recurrent infection and complications 4 weeks after the end of therapy. The most frequent T-types of 129 isolates were T12, T4, and T1 at 40.3%, 27.1%, and 9.3%.
Of the 129, 3 refused to take the drug and 14 did not return for follow-up. The 112 we evaluated experienced clinical efficacy and their symptoms were ameliorated. Six still had GAS from pharyngeal swabs at the end of therapy. Isolates from 5 were identical to initial strains in T-type and PFGE pattern.
All 108 observed within 1 month after the end of administration had no complications, but 7 had a recurrence of GAS infection. Four still had GAS from pharyngeal swabs at the end of therapy and isolates from one differed from initial strains in T-type and PFGE pattern. Adverse effects were diarrhea observed in 3 and vomiting in 1.
Key word
Streptococcus pyogenes, cefcapene pivoxil, pharyngitis
Received
May 22, 2006
Accepted
October 2, 2006
Jpn. J. Chemother. 54 (6): 526-530, 2006
